Opexa Therapeutics (OPXA) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 11, 2016 4:01 PM EDTTHE WOODLANDS, TX -- (Marketwired) -- 08/11/16 -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including Tcelna for multiple sclerosis (MS) and OPX-212 for neuromyelitis optica (NMO), today reported financial results for the quarter ended June 30, 2016, and provided an update on the Company's clinical development and corporate activities.
"During the second quarter we continued to advance our Phase 2b Abili-T trial in secondary progressive multiple sclerosis towards completion and we are excited to approach this significant milestone in the development of our personalized immunotherapy,... More
